Earth Science Tech, Inc. (ETST) Enters New Stage of Cannabis Industry Growth
- Cannabis industry expected to reach $24.5 billion in sales within four years
- Company expanding into Canada ahead of expected nationwide legalization
- Medical diagnostic device set for clinical tests to validate detection of STDs
With the sunny investment disposition toward marijuana and blockchain-related industries carrying over from late 2017’s marketplace into the new year (http://nnw.fm/3Kzml), Florida-based Earth Science Tech, Inc. (OTC: ETST) is optimistic about its ability to serve the medical and recreational needs of a growing population of cannabis users. The biotechnology company has established a research agreement with the University of Central Oklahoma and DV Biologics Laboratory to study and advance the health care benefits of its high-grade hemp CBD oil, placed its cannabidiol (CBD) food products in retail stores throughout the country, established a non-profit foundation to help underprivileged patients use its products and acquired Quebec, Canada-based Canna Inno Laboratories Inc. in a bid to expand into that country as it prepares to legalize the recreational use of marijuana on a national basis later this year.
Earth Science Tech, Inc. announced in May 2014 that it was entering the legal cannabis and medical marijuana industry as a natural progression of its mission to deliver wellness and alternative medicine options to American consumers. In the nearly four years since, a growing number of states have legalized medicinal and recreational uses for marijuana derivatives as popular sentiment has shifted toward acceptance of the drug despite its continued classification as a controlled substance by the federal government. The revolution in Canada that is expected to result in full legalization this summer has outpaced U.S. attitudes and provided a near-neighbor alternative for U.S. businesses that continue to encounter market obstacles at home.
Variances in forecasts about the market potential for the legal cannabis industry are measured in billions of dollars nowadays; cannabis industry analysts Arcview Market Research, in partnership with BDS Analytics, predicts that the market will reach $24.5 billion in sales within the next three to four years with a 28 percent CAGR that follows on a 33 percent increase between 2016 and 2017 despite ongoing federal prohibition (http://nnw.fm/pEAM5). As this market potential grows, Earth Science Tech is working to uplist under the OTCQB’s regulations for new Tier II Regulation A+ companies, with hopes for SEC approval by March.
The proposed uplisting will underpin efforts to raise an additional $4 million in operating capital so the company can complete planned projects advancing its brand in the United States and Canada. In December, Earth Science Tech announced a CBD product revamp and brand education strategy (http://nnw.fm/3nYfW) that it expected to launch by the end of January, along with a renewed push for major donors to help its non-profit foundation and a collaboration with a start-up accelerator in Canada to help it ramp up its brand awareness.
In February, the company plans to begin a nine-month series of human clinical trials on its new CBD formulation, which is designed to decrease cravings and the negative effects of withdrawal in addicts. If the trials prove successful, the product is set to launch in 2019 as a new addition to the stable of Earth Science Tech patent-pending offerings.
“We look to hit the ground running in 2018 with all we have lined-up in the first quarter,” president, director and COO Nickolas Tabraue stated in a news release. “We have other exciting discussions that are progressing well, and we will share those once any material developments have been finalized. Our story and vision will be seen very soon and we greatly appreciate all who have believed in us since the beginning.”
Another aspect of Earth Science Tech’s mission is to develop low-cost, noninvasive home-use diagnostic tools for sexually transmitted infections and/or diseases. The company’s first medical device has been labeled MSN-2, which is set for clinical tests under an agreement with Laboratories BNK Canada to ensure the device meets regulatory requirements as part of the company’s bid to meet the specific needs of women. Earth Science Tech has already established the MSN-2 device’s ability to detect chlamydia, and it now aims to validate similar results for gonorrhea, another sexually transmitted disease that can have permanent consequences for patients if untreated. The company also plans to add testing to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. The diagnostic testing market for STDs is expected to grow to $108 billion by 2019, according to Transparency Market Research.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Cannabis industry expected to reach $24.5 billion in sales within four years
- Company expanding into Canada ahead of expected nationwide legalization
- Medical diagnostic device set for clinical tests to validate detection of STDs
With the sunny investment disposition toward marijuana and blockchain-related industries carrying over from late 2017’s marketplace into the new year (http://nnw.fm/3Kzml), Florida-based Earth Science Tech, Inc. (OTC: ETST) is optimistic about its ability to serve the medical and recreational needs of a growing population of cannabis users. The biotechnology company has established a research agreement with the University of Central Oklahoma and DV Biologics Laboratory to study and advance the health care benefits of its high-grade hemp CBD oil, placed its cannabidiol (CBD) food products in retail stores throughout the country, established a non-profit foundation to help underprivileged patients use its products and acquired Quebec, Canada-based Canna Inno Laboratories Inc. in a bid to expand into that country as it prepares to legalize the recreational use of marijuana on a national basis later this year.
Earth Science Tech, Inc. announced in May 2014 that it was entering the legal cannabis and medical marijuana industry as a natural progression of its mission to deliver wellness and alternative medicine options to American consumers. In the nearly four years since, a growing number of states have legalized medicinal and recreational uses for marijuana derivatives as popular sentiment has shifted toward acceptance of the drug despite its continued classification as a controlled substance by the federal government. The revolution in Canada that is expected to result in full legalization this summer has outpaced U.S. attitudes and provided a near-neighbor alternative for U.S. businesses that continue to encounter market obstacles at home.
Variances in forecasts about the market potential for the legal cannabis industry are measured in billions of dollars nowadays; cannabis industry analysts Arcview Market Research, in partnership with BDS Analytics, predicts that the market will reach $24.5 billion in sales within the next three to four years with a 28 percent CAGR that follows on a 33 percent increase between 2016 and 2017 despite ongoing federal prohibition (http://nnw.fm/pEAM5). As this market potential grows, Earth Science Tech is working to uplist under the OTCQB’s regulations for new Tier II Regulation A+ companies, with hopes for SEC approval by March.
The proposed uplisting will underpin efforts to raise an additional $4 million in operating capital so the company can complete planned projects advancing its brand in the United States and Canada. In December, Earth Science Tech announced a CBD product revamp and brand education strategy (http://nnw.fm/3nYfW) that it expected to launch by the end of January, along with a renewed push for major donors to help its non-profit foundation and a collaboration with a start-up accelerator in Canada to help it ramp up its brand awareness.
In February, the company plans to begin a nine-month series of human clinical trials on its new CBD formulation, which is designed to decrease cravings and the negative effects of withdrawal in addicts. If the trials prove successful, the product is set to launch in 2019 as a new addition to the stable of Earth Science Tech patent-pending offerings.
“We look to hit the ground running in 2018 with all we have lined-up in the first quarter,” president, director and COO Nickolas Tabraue stated in a news release. “We have other exciting discussions that are progressing well, and we will share those once any material developments have been finalized. Our story and vision will be seen very soon and we greatly appreciate all who have believed in us since the beginning.”
Another aspect of Earth Science Tech’s mission is to develop low-cost, noninvasive home-use diagnostic tools for sexually transmitted infections and/or diseases. The company’s first medical device has been labeled MSN-2, which is set for clinical tests under an agreement with Laboratories BNK Canada to ensure the device meets regulatory requirements as part of the company’s bid to meet the specific needs of women. Earth Science Tech has already established the MSN-2 device’s ability to detect chlamydia, and it now aims to validate similar results for gonorrhea, another sexually transmitted disease that can have permanent consequences for patients if untreated. The company also plans to add testing to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. The diagnostic testing market for STDs is expected to grow to $108 billion by 2019, according to Transparency Market Research.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
